Trial reportPediatric research2026
L.Fermentum CECT5716 and B.Breve CECT7263 on premature infants morbidities: a randomized clinical trial.
Trial report in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synergistic regulation of gut microbiota and metabolites by breast milk and probiotics in the prevention of neonatal necrotizing enterocolitis: mechanisms and prospects.Translational pediatrics · 2026Review
- Gut microbial metabolites in inflammation-associated colorectal cancer: mechanisms and therapeutic implications.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study examined the effects of two doses of probiotics isolated from human milk on the incidences of necrotizing enterocolitis (NEC) and mortality in preterm infants.
methodsThis multicenter, randomized, double-blind study involved 583 very low birth weight preterm neonates (≤32 6/7 weeks, <1500 g) who started enteral nutrition within 72 h of birth (>5 ml/kg/day) and received either a high-dose (HD, 1 × 10
resultsThe probiotic combination was well tolerated with no adverse effects. The NEC (2.5% vs. 1.3%; p = 0.156) and mortality (3.9% vs. 3.6%; p = 0.685) rates were not significantly different between the groups (HD vs. LD). These rates were lower than those reported in a co-temporal cohort in the region (SEN1500 cohort).
conclusionNo significant differences were found between the HD and the LD of the LC40 and BfM26 combination in the incidence of NEC and all-cause mortality. The incidence rates of death and NEC were lower in this study than in the SEN1500 cohort, suggesting that the low dose may suffice for preterm infants. This study supports the safety and tolerability of these probiotics in preterm infants. IMPACT: The study responds to scientific societies' request for more clinical trials to strengthen the currently low level of evidence on probiotics' safety and benefits for preterm infants. The study presents evidence supporting the safety and the effect of two different doses of a combination of two human milk-derived probiotic strains in preterm infants. The study indicates that a low dose of probiotics may be sufficient to achieve beneficial effects in preterm infants. These findings will inform future research on optimizing probiotic dosing in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.